United Therapeutics prepares for major trial tests in the first half of 2026 after a successful stock run.

United Therapeutics Corporation has seen a significant uptick in performance over the past year, with its stock price increasing by approximately 62.5% from early March 2025 to March 1st, 2026, outperforming the S&P 500 during the same period. This rally was primarily fueled by the strong sales of Tyvaso, particularly the Tyvaso DPI, as well as positive advancements in late-stage programs for Tyvaso and ralinepag, such as the TETON program and the ADVANCE OUTCOMES trial. Additionally, the company provided optimistic guidance regarding double-digit revenue growth and set a target of achieving a multi-billion dollar run-rate by 2027.

In terms of growth prospects, United Therapeutics has shifted towards an expansion-led narrative, moving away from its previous focus on legacy products. Key drivers of growth include the potential expansion of Tyvaso into wider fibrosing lung disease populations through the TETON program and the potential launch of oral ralinepag pending positive results from the ADVANCE OUTCOMES trial. The company reported record revenues in 2025 and expects continued double-digit revenue growth, aiming for a $4 billion annualized run-rate by the second half of 2027, pending successful late-stage readouts and regulatory advancements.

United Therapeutics boasts strong quality metrics, with an operating margin close to 47.7% and a Return On Invested Capital (ROIC) of about 21.71%, indicating high profitability and capital efficiency compared to industry peers. The company holds a solid position in prostacyclin therapies, leveraging its expertise in home infusion and inhaled delivery. With a conservative balance sheet and effectively zero net debt, United Therapeutics has flexibility for potential mergers and acquisitions or further investments in research and development.

Regarding valuation, United Therapeutics appears to be reasonably priced for a company demonstrating both growth and profitability. Despite a forward P/E ratio of about 14.91, below the market average, the market still accounts for execution risk in pricing the stock. The company’s free cash flow yield, while solid, falls below its five-year average due to increased reinvestment for growth. As the company continues to deliver on its late-stage programs and organ initiatives, there is potential for valuation upside, but any negative outcomes could lead to a reduced multiple.

Market sentiment surrounding United Therapeutics has shifted positively in recent months, with a notable decrease in short interest as the stock price surged. Analyst attention has increased following strong quarterly results and encouraging guidance from management. However, key risks remain, including clinical trial outcomes, regulatory challenges, concentration risks tied to specific products, and potential operational complexities in manufacturing and distribution. Despite these risks, a positive outlook hinges on upcoming trial results and continued commercial momentum, positioning United Therapeutics for future success.